|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.75|
Mallinckrodt plc, a global biopharmaceutical company, announced today that Japan's Ministry of Health, Labour and Welfare (MHLW) approved the CELLEX® extracorporeal photopheresis (ECP) system for the treatment of steroid-resistant or intolerant chronic graft versus host disease (cGvHD) in adults.
The Mallinckrodt board and management has entirely abandoned shareholder interests, attempting to push through a Chapter 11 restructuring plan (their case pending before the U.S. District of Delaware Bankruptcy Court) that will extinguish all shareholder interests, unnecessarily turn all shareholder equity over to a handful of bondholders, and enrich management with a 10% allocation of the reorganized company when they currently own less than 0.03% of the existing company.
Mallinckrodt (MNKKQ) closed the most recent trading day at $0.23, moving +1.7% from the previous trading session.